Insights

Innovative Technology Mytos specializes in automated cell manufacturing using advanced robotics and AI-driven platforms, making it a compelling partner for organizations seeking scalable and efficient cell therapy production and R&D testing solutions.

Strategic Partnerships Recent collaborations with StemSight, Rinri Therapeutics, Novadip, and Aspen Neuroscience highlight opportunities for joint ventures and contract manufacturing agreements targeting next-generation cell therapies and neurodegenerative disease treatments.

Funding & Growth With $19 million in Series A funding led by prominent venture capital firms, Mytos is positioned for expansion, offering potential for sales of new machinery, platform upgrades, or integrated solutions to accelerate clients' clinical and commercial programs.

Market Focus Mytos serves the growing biotech and pharmaceutical sectors, particularly those involved in regenerative medicine and drug discovery, providing a pathway to capture clients aiming to shorten development timelines and increase therapy accessibility.

Customer Engagement Targeting organizations involved in cell therapy and personalized medicine, Mytos offers opportunities to sell automated manufacturing devices, contract manufacturing services, and technical support to biotechnology firms seeking to optimize their cell production processes.

Similar companies to Mytos

Mytos Tech Stack

Mytos uses 8 technology products and services including CUDA, Google Hosted Libraries, MongoDB, and more. Explore Mytos's tech stack below.

  • CUDA
    Audio, Video, Graphics
  • Google Hosted Libraries
    Content Delivery Network
  • MongoDB
    Database
  • Google Workspace
    Email
  • Linux
    Programming Languages
  • Python
    Programming Languages
  • Lua
    Programming Languages
  • OpenResty
    Web Servers

Mytos's Email Address Formats

Mytos uses at least 2 format(s):
Mytos Email FormatsExamplePercentage
First@cytera.bioJohn@cytera.bio
100%
First@mytos.bioJohn@mytos.bio
70%
Last@mytos.bioDoe@mytos.bio
30%

Frequently Asked Questions

Where is Mytos's headquarters located?

Minus sign iconPlus sign icon
Mytos's main headquarters is located at 80 Wood Lane London, England United Kingdom. The company has employees across 2 continents, including EuropeNorth America.

What is Mytos's official website and social media links?

Minus sign iconPlus sign icon
Mytos's official website is mytos.bio and has social profiles on LinkedInCrunchbase.

What is Mytos's SIC code NAICS code?

Minus sign iconPlus sign icon
Mytos's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mytos have currently?

Minus sign iconPlus sign icon
As of February 2026, Mytos has approximately 48 employees across 2 continents, including EuropeNorth America. Key team members include Ceo/Co-Founder: A. A.Chief Of Staff: C. M.Co-Founder & Cco: I. W.. Explore Mytos's employee directory with LeadIQ.

What industry does Mytos belong to?

Minus sign iconPlus sign icon
Mytos operates in the Biotechnology Research industry.

What technology does Mytos use?

Minus sign iconPlus sign icon
Mytos's tech stack includes CUDAGoogle Hosted LibrariesMongoDBGoogle WorkspaceLinuxPythonLuaOpenResty.

What is Mytos's email format?

Minus sign iconPlus sign icon
Mytos's email format typically follows the pattern of First@cytera.bio. Find more Mytos email formats with LeadIQ.

How much funding has Mytos raised to date?

Minus sign iconPlus sign icon
As of February 2026, Mytos has raised $19M in funding. The last funding round occurred on Nov 30, 2023 for $19M.

When was Mytos founded?

Minus sign iconPlus sign icon
Mytos was founded in 2016.

Mytos

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Mytos automates production of stem cell-derived therapies - enabling them to scale to millions of patients at low cost. Our custom iDEM robotics platform powers our automated CDMO.

Our announced partnerships include neurons for treating Parkinson's, bone for bone repair, corneal cells for blindness, and auditory neurons for hearing loss (and we have more to announce). Cells produced on our iDEM platform will be going into patients by 2027.

Mytos has raised over $24m from leading investors, including YCombinator, Buckley Ventures and IQ Capital - as well as founders and execs from companies like Kite, Sana, Dropbox, and Revolut. Our team is made up of brilliant engineers from companies like Dyson and Autodesk - working hand-in-hand with Nature-published scientists. 

We're hiring now - visit our website to see open positions

Section iconCompany Overview

Headquarters
80 Wood Lane London, England United Kingdom
Website
mytos.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $19M

    Mytos has raised a total of $19M of funding over 3 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $19M.

  • $1M$10M

    Mytos's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $19M

    Mytos has raised a total of $19M of funding over 3 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $19M.

  • $1M$10M

    Mytos's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.